Roche Aktie News

New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1 Almost one third of surveyed European millennials eligible for routine cervical screening have postponed or skipped their appointment.1 Cervical cancer is one of the most preventable cancers, with almost all cases avoidable through vaccination and regular screenings.2 BASEL, Switzerl...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive multiple sclerosis.

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, sig...

Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) rose 10% to 2.3p after the company revealed encouraging early results from a study showing its cancer cell detection platform works seamlessly with Roche's leading diagnostic equipment. The Guildford-based biotech, which specialises in analysing circulating tumour cells, live cancer cells that move through the bloodstream, presented the findings ...

CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) has unveiled early results from a study that links its cancer cell detection technology with Roche's widely used diagnostic equipment, a step that could make blood-based cancer testing easier to integrate into hospital laboratories. The Guildford-based company, which focuses on analysing circulating tumour cells, live cancer cells that break away from tumo...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 6-9, 2025 in Orlando, Florida. “The data we will present...